Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C90H163N27O25S |
Molecular Weight | 2055.488 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 20 / 20 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O
InChI
InChIKey=BROGCIMRGWLMOO-SJPGHYFNSA-N
InChI=1S/C90H163N27O25S/c1-15-48(12)68(95)84(137)110-60(41-67(123)124)81(134)105-55(28-31-64(93)119)75(128)104-56(29-32-65(94)120)77(130)115-69(47(10)11)85(138)111-59(39-45(6)7)80(133)113-62(42-118)82(135)103-54(27-23-37-101-90(98)99)76(129)116-70(49(13)16-2)86(139)108-52(25-19-21-35-92)73(126)109-58(38-44(4)5)79(132)106-57(30-33-66(121)122)78(131)117-71(50(14)17-3)87(140)107-51(24-18-20-34-91)72(125)102-53(26-22-36-100-89(96)97)74(127)114-63(43-143)83(136)112-61(88(141)142)40-46(8)9/h44-63,68-71,118,143H,15-43,91-92,95H2,1-14H3,(H2,93,119)(H2,94,120)(H,102,125)(H,103,135)(H,104,128)(H,105,134)(H,106,132)(H,107,140)(H,108,139)(H,109,126)(H,110,137)(H,111,138)(H,112,136)(H,113,133)(H,114,127)(H,115,130)(H,116,129)(H,117,131)(H,121,122)(H,123,124)(H,141,142)(H4,96,97,100)(H4,98,99,101)/t48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,68-,69-,70-,71-/m0/s1
Molecular Formula | C90H163N27O25S |
Molecular Weight | 2055.488 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 20 / 20 |
E/Z Centers | 9 |
Optical Activity | UNSPECIFIED |
FEXAPOTIDE is a protein drug that is under development for the treatment of benign prostatic hyperplasia (prostate enlargement, BPH) and for low grade localized prostate cancer. It safely targets prostate glandular cells that have proliferated in BPH. FEXAPOTIDE works by a mechanism of inducing apoptosis.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29380128
FEXAPOTIDE 2.5 mg in 10 ml phosphate buffered saline (PBS) sterile solution.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:12:31 GMT 2023
by
admin
on
Sat Dec 16 02:12:31 GMT 2023
|
Record UNII |
9L8TV1O7E0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
G04CX04
Created by
admin on Sat Dec 16 02:12:31 GMT 2023 , Edited by admin on Sat Dec 16 02:12:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
16207730
Created by
admin on Sat Dec 16 02:12:31 GMT 2023 , Edited by admin on Sat Dec 16 02:12:31 GMT 2023
|
PRIMARY | |||
|
C174582
Created by
admin on Sat Dec 16 02:12:31 GMT 2023 , Edited by admin on Sat Dec 16 02:12:31 GMT 2023
|
PRIMARY | |||
|
492447-54-8
Created by
admin on Sat Dec 16 02:12:31 GMT 2023 , Edited by admin on Sat Dec 16 02:12:31 GMT 2023
|
PRIMARY | |||
|
10199
Created by
admin on Sat Dec 16 02:12:31 GMT 2023 , Edited by admin on Sat Dec 16 02:12:31 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545061
Created by
admin on Sat Dec 16 02:12:31 GMT 2023 , Edited by admin on Sat Dec 16 02:12:31 GMT 2023
|
PRIMARY | |||
|
9L8TV1O7E0
Created by
admin on Sat Dec 16 02:12:31 GMT 2023 , Edited by admin on Sat Dec 16 02:12:31 GMT 2023
|
PRIMARY | |||
|
DB05493
Created by
admin on Sat Dec 16 02:12:31 GMT 2023 , Edited by admin on Sat Dec 16 02:12:31 GMT 2023
|
PRIMARY | |||
|
CD-04
Created by
admin on Sat Dec 16 02:12:31 GMT 2023 , Edited by admin on Sat Dec 16 02:12:31 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |